Rembak-Szynkiewicz Justyna, Mazgaj Patrycja, Szopin'ski Tomasz, Badzin'ski Arkadiusz, Hebda Anna, Wojcieszek Piotr
Radiology and Diagnostic Imaging Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Department of Urology, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.
J Contemp Brachytherapy. 2025 Jun;17(3):202-212. doi: 10.5114/jcb.2025.152544. Epub 2025 Jun 30.
The aim of this paper was to present a rare complication of orchiepididymitis in a patient treated with brachytherapy (BT) for prostate cancer, who underwent trans-ureteral resection of the prostate (TURP) four weeks after BT. A 73-year-old patient with prostate cancer (intermediate-risk group) was eligible for high-dose-rate (HDR) BT combined with androgen deprivation therapy (ADT) for 6 months (leuprorelin). Due to increased symptoms, such as urinary retention after BT, the patient required catheterization. Additionally, bacterial inflammation in the lower urinary tract and prostate was present. Due to prolonged micturition disorders, TURP was performed, leading to chronic orchiepididymitis four months after completion of BT and three months after catheter removal following TURP. Due to long-term inflammation, which was resistant to treatment, the left testicle with left epididymis was removed. Unfortunately, inflammatory symptoms occurred post-operatively in the bed and the left groin. Since these symptoms of varying severity continued, anti-inflammatory drugs and analgesics were introduced. TURP performed too quickly after HDR-BT might cause severe complications. Extreme caution regarding TURP should be exercised in patients undergoing BT. Conservative and pharmacological treatment must be introduced in the occurrence of urinary disorders after BT, and any intervention (TURP) should be performed at least 3-6 months after BT. This is especially crucial because of the development of radiation effect over time.
本文的目的是介绍一名接受前列腺癌近距离放射治疗(BT)的患者发生的罕见附睾炎并发症,该患者在BT治疗四周后接受了经尿道前列腺切除术(TURP)。一名73岁的前列腺癌患者(中危组)符合接受高剂量率(HDR)BT联合雄激素剥夺治疗(ADT)6个月(亮丙瑞林)的条件。由于BT后出现诸如尿潴留等症状加重,患者需要导尿。此外,下尿路和前列腺存在细菌感染。由于排尿障碍持续存在,患者接受了TURP,导致在BT完成四个月后以及TURP后拔除导尿管三个月后发生慢性附睾炎。由于长期炎症对治疗有抵抗性,切除了左侧睾丸及附睾。不幸的是,术后在床上和左侧腹股沟出现了炎症症状。由于这些不同程度的症状持续存在,开始使用抗炎药和镇痛药。HDR-BT后过快进行TURP可能会导致严重并发症。接受BT的患者在进行TURP时应极其谨慎。BT后出现排尿障碍时必须采取保守和药物治疗,任何干预措施(TURP)应在BT后至少3至6个月进行。由于放射效应会随时间发展,这一点尤为关键。